Seite auswählen

The American pharmaceutical company Pfizer and the Indian biotech company Biocon have terminated their collaboration. Both companies cooperated in the sale of insulin. The consensual separation with immediate effect comes after about a year, because Pfizer’s biogenerics strategy included other priorities. Biocon now lacks a partner for its worldwide marketing rights of insulin products.

Meanwhile share prizes have reacted in different ways. While Biocon shares have already fallen by 6 percent, Pfizer shares on the other hand have risen by 1.9 percent on the US stock exchange.

[ilink url=““] link to source (Handelsblatt)[/ilink]